You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Si-ROMP Hybrid Reagent/Scavengers for High Throughput Chemistry

    SBC: MATERIA, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): This Fast Track Small Business Technology Transfer study between Materia, Inc. and the University of Kansas intends to build upon successes of our current STTR Phase II grant (R41GM076765-02) which expires on March 31,2011. This proposal is a collaborative effort between the University of Kansas and Materia, Inc. in Pasadena, CA that aims to develop and scale-u ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. visiBabble, a System for Early Speech Intervention

    SBC: Speech Technology and Applied Research Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): This project will develop visiBabble, sound recognition software to provide real-time contingent visual reinforcement of vocalizations produced by infants or preschool children. This program is intended for children who are delayed in the frequency and variety of pre-speech vocalizations they produce and, hence, are at risk for being non-speaking. The visiBabbl ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  3. Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

    SBC: PACDNA LLC            Topic: NCI

    Project Summary/Abstract Mutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeuticintervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a singlemutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitorshas heightened the importance of alternative methods targeting the o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Micro-targeted Computerized Alcohol Misuse Intervention System for Health Care

    SBC: RESEARCH CIRCLE ASSOCIATES            Topic: NIAAA

    DESCRIPTION provided by applicant Alcohol misuse continues to pose a major burden for public health Screening and brief intervention for alcohol misuse in primary care settings has been recommended for decades and the evidence base supporting it in primary care is robust However many primary care providers do not intervene in alcohol misuse and those that do often fail to do so systematica ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Retroviral Vectors for Safe and Efficacious Gene Therapy

    SBC: Neumedicines Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Phase I funding for this project supported the successful development of the backbone for a new generation of retroviral gene therapy vectors that contain safety and efficacy features designed to overcome the problems that have been found with retroviral vectors used in current clinical trials. The model disease targeted is the well-studied genetic disease Aden ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Intra procedure Deformable Ultrasound MRI Fusion for Prostate Biopsies

    SBC: ZMK Medical Technologies, Inc.            Topic: 102

    This Phase II proposal is a continuation of our successful Phase I grant whose overarching goal is to develop a more robust and accurate method for the deformable fusion of pre operative magnetic resonance images MRI and intra procedure trans rectal ultrasound TRUS images to guide prostate biopsy Prostate cancer is a major cause of death in the U S and biopsy is the gold standard for its dia ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Alkontrol herbal for Treating Alcohol Abuse

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: 350

    This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia InternationalIncNPIand McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholismExcessive use of alcohol accounts for much of the public health burden related to alcohol use disordersincluding fetal alcohol syndromefatal motor crashesaccidents and ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy

    SBC: FILTRO MEDICAL INC.            Topic: 102

    PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image- guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target drugs in situ through a variet ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skinlesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are thetwo most common types of CTCL. Although treatments exist, they are mainly palliative with low response anddurability of response without any cure. The objective response rate rem ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a clinical hemoglobin modulator

    SBC: Phoenicia Biosciences, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant The thalassemias and sickle cell disease are serious genetic blood diseases which are WHO designated as a growing global health burden The disorders decrease production or alter structure of the b chain of adult hemoglobin A and are characterized by anemia chronic organ damage and early mortality HbF is another type of normal hemoglobin which is suppres ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government